trending Market Intelligence /marketintelligence/en/news-insights/trending/tcc3WVbJyhw5l5b5tJ2W4Q2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Epizyme closes $172.5M offering to raise funds for cancer treatment

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Epizyme closes $172.5M offering to raise funds for cancer treatment

Epizyme Inc. has closed a public offering of shares, raising $172.5 million to fund global development of the company's cancer treatment tazemetostat.

Cambridge, Mass.-based Epizyme closed two separate underwritten public offerings of 11.5 million common shares and 350,000 non-voting Series A convertible preferred stock, according to a March 12 press release.

Underwriters fully exercised their option to purchase additional shares in the offering. Each share was offered at $11.50, while each Series A stock was $115 apiece.

The company said net proceeds from the offering will be used to fund global development of tazemetostat outside of Japan. The medicine is under development for epithelioid sarcoma, a rare type of soft tissue cancer, and follicular lymphoma, a type of non-Hodgkin lymphoma. Remaining funds will be used to identify other drug candidates and for working capital and general corporate purposes.

Joint book-running managers on the offering were Jefferies, Citigroup and Cowen, while Wedbush PacGrow acted as lead manager and H.C. Wainwright & Co. as co-manager.